Diabetes Drug Avandia: Safe for Heart?

Study Shows No Safety Issues for Diabetes Patients Who Also Had Heart Bypass Surgery

From the WebMD Archives

April 3, 2008 (Chicago) -- The diabetes drug Avandia proved safe in a study pitting it against a placebo in nearly 200 people with diabetes who had undergone heart bypass surgery, researchers say.

Compared with patients on a placebo, patients taking Avandia were no more likely to have a heart attack or stroke, need another procedure to clear blocked arteries, or die.

"No safety issues were identified in this high-cardiovascular-risk population," says Olivier F. Bertrand, MD, of Laval University in Quebec City, Canada.

The drug did not slow the progression of plaque buildup over the 12-month study period, which was the primary goal of the study.

However, there were some signs the drug was helping, Bertrand says. People taking Avandia had lower blood sugar levels, higher levels of HDL "good" cholesterol, and lower levels of a blood marker of inflammation known as C-reactive protein, compared with those on a placebo. The diabetes drug also had favorable effects on blood clotting.

Bertrand presented the findings here at the American College of Cardiology's annual meeting.

The findings are reassuring in light of concerns that the class of drugs to which Avandia and Actos belong may increase heart risks, says Robert Eckel, MD, a past president of the American Heart Association and a professor of endocrinology at the University of Colorado.

One study last year suggested Avandia may increase a person's risk of heart attack and death from heart disease. Then later in the year, the FDA mandated that both Avandia and Actos carry a "black box" warning that the drugs may trigger heart failure.

Bertrand says that a number of ongoing studies will help further pinpoint Avandia's role in people with type 2 diabetes and coronary artery disease.

GlaxoSmithKline, which makes Avandia, funded the trial.

WebMD Health News Reviewed by Louise Chang, MD on April 03, 2008



American College of Cardiology's 57th Annual Scientific Session, Chicago, March 29 - April 1, 2008.

Olivier F. Bertrand, MD, assistant professor, Laval University, Quebec City, Canada.

Robert Eckel, MD, past president, American Heart Association; professor of endocrinology, University of Colorado.

© 2008 WebMD, LLC. All rights reserved.